HDAC6 and neoplasm: Liu et al. (2019) discovered that MiR-601 could downregulate HDAC6 expression in ESCC, which eventually suppressed proliferation, invasion, and migration of ESCC cells. Cao et al. (2018) reported that HDAC6 inhibition using the selective inhibitor ACY1215 could inhibit cellular proliferation as well as induce G2/M arrest and apoptosis via miR-30d/phosphoinositide 3-kinase (PI3K)/AKT/mTOR and ERK pathways. Moreover, HDAC6 may be among the targets of bortezomib tumor suppression in esophageal carcinoma cells (Ao et al., 2019).